AMLX Stock Price
Amylyx Pharmaceuticals, Inc.
AMLX stock price is $28.27 (+0.80% on the day), giving Amylyx Pharmaceuticals, Inc. a market cap of $3.52B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
AMLX Stock Overview
- Price
- $28.27
- Previous close
- $28.04
- Open
- $27.72
- Market cap
- $3.52B
- P/E ratio
- -24.3
- 52-week range
- $10.83 - $41.14
- 1-year price target
- $40.82
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 40
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AMLX | $28.27 | +0.8% | 230.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Amylyx Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW